Physician profile

Hannah Chung

Vascular & Interventional Radiology · Brooklyn, NY

NPI 1831533298

$2,545.43

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

See the full distribution for Vascular & Interventional Radiology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$241.88

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Terumo Medical Corporation $1,230.48 2019
Sirtex Medical INC $668.56 2019
Argon Medical Devices, INC. $354.86 2019
Penumbra, INC. $112.50 2023 Penumbra System
Abbott Laboratories $104.76 2024 Jeti All In One Non-Sterile Kit
Boston Scientific Corporation $27.46 2020
Ge Healthcare $24.62 2024
Medtronic, INC. $22.19 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Hannah Chung

$2,545.43

in general payments reported 2019-2025

Years
2019-2024
Top company
Terumo Medical Corporation

https://glasscript.com/doctor/2781789/hannah-chung

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.